Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CCKBR | P32239 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25849159 | 0.87 | CYP2C19 (0.46) | ALDH1A1CYP2C19CYP1A2MAPTMEN1 | |
| SCHEMBL25849170 | 0.87 | PKM (0.49) | ALDH1A1TAAR1CYP2C19CYP1A2MAPT | |
| SCHEMBL25849173 | 0.74 | TDP1 (0.44) | ALDH1A1KMT2ASMN1; SMN2L3MBTL1MAPK1 | |
| SCHEMBL25849155 | 0.72 | PKM (0.51) | ALDH1A1CYP2C19CYP1A2MAPTKMT2A | |
| SCHEMBL12409525 | 0.71 | HTT (0.62) | ALDH1A1TAAR1MAPTMEN1POLB | |
| SCHEMBL11448075 | 0.69 | KMT2A (0.56) | ALDH1A1TAAR1MAPTMEN1POLB | |
| SCHEMBL6796154 | 0.69 | KMT2A (0.62) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL11957306 | 0.69 | HPGD (0.59) | ALDH1A1TAAR1CYP2C19MAPTMEN1 | |
| SCHEMBL11447419 | 0.68 | MEN1 (0.58) | ALDH1A1TAAR1MAPTMEN1POLB | |
| SCHEMBL9400067 | 0.68 | TAAR1 (0.54) | ALDH1A1TAAR1MAPTMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203474-A1 | COMPOUND, SOLID CARRIER INCLUDING THE SAME AND METHOD FOR PREPARING NUCLEIC ACID | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203474-A1 | COMPOUND, SOLID CARRIER INCLUDING THE SAME AND METHOD FOR PREPARING NUCLEIC ACID | SNRPA, NSUN2, POLRMT | ALDH1A1 2601/4885TAAR1 2239/4885CYP2C19 2120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.